Sep 30, 2023

Entrada Therapeutics Q3 2023 Earnings Report

Total Revenue
$43.7M
EPS
$1.02
Previous year: -$0.8
-227.5%
R&D Expenses
$22.2M
G&A Expenses
$7.5M
Gross Profit
$42.9M
Cash and Equivalents
$354M
Previous year: $53.3M
+563.2%
Free Cash Flow
-$25.9M
Previous year: -$28.3M
-8.3%
Total Assets
$485M
Previous year: $274M
+76.7%

Entrada Therapeutics

Entrada Therapeutics

Entrada Therapeutics Revenue by Segment